Introducing the UK Molecular Radiotherapy Consortium

Introducing the UK Molecular Radiotherapy Consortium

The UK Molecular Radiotherapy Consortium is an alliance of clinicians and patient advocates formed to support equitable access to evidence-based theranostic MRT across the UK.
Read More
How consistent terminology can aid integration of radioligand therapy

How consistent terminology can aid integration of radioligand therapy

Inconsistent use of terminology presents challenges to building awareness of radioligand therapy and appropriately integrating it into care.
Read More
Call to share experiences of integrating radioligand therapy into care

Call to share experiences of integrating radioligand therapy into care

The Health Policy Partnership wants to better understand what actions and initiatives have taken place to improve the delivery of radioligand therapy.
Read More
World Theranostics Day 2022: what are theranostics and how can we use them?

World Theranostics Day 2022: what are theranostics and how can we use them?

On World Theranostics Day 2022, HPP explores the ongoing innovation and advancement in the field of theranostics.
Read More
We need continued research to ensure wider access to innovative therapies as soon as they are approved

We need continued research to ensure wider access to innovative therapies as soon as they are approved

In this guest blog, Dr Erik Briers emphasises the need for continued research and planning to make radioligand therapy a more viable treatment option.
Read More
SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe highlights patient experience of radioligand therapy in new video

SPARC-Europe has released a video of patient testimonies to raise awareness of the benefits of radioligand therapy and outline some of the challenges to access.
Read More
New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

The Health Policy Partnership has published a series of templates to support independent applications of the Radioligand Therapy Readiness Assessment Framework.
Read More
Conference session considers what is needed for radioligand therapy in prostate cancer

Conference session considers what is needed for radioligand therapy in prostate cancer

The Health Policy Partnership held a session on multidisciplinary collaboration for health system readiness at the 13th European Multidisciplinary Congress on Urological Cancers.
Read More
ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

The Health Policy Partnership has published a poster at the 63rd annual meeting of the American Society of Hematology (ASH).
Read More
New cancer therapies: how workforce capacity impacts treatment implementation

New cancer therapies: how workforce capacity impacts treatment implementation

For his guest blog, Dr Martin Rolles explores how lack of workforce planning and specialist training can be a barrier to implementing new cancer therapies.
Read More
Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

Leading experts join HPP and Avalere to examine readiness for radioligand therapy in the US

The Health Policy Partnership (HPP) and Avalere Health recently held a webinar on the use of radioligand therapy and readiness for its future integration in the US.
Read More
Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Neuroendocrine cancer and radioligand therapy: how patient involvement can shape the regulatory process

Nikie Jervis explores the history of regulatory approval for radioligand therapy in the UK, and the importance of patient involvement, in her guest blog.
Read More